🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Adding Bempedoic Acid to Ezetimibe and statin post ACS did not lower LDL-C beyond other patients in the control. #ESCPrev2025

🚨 Don’t miss #ACNAP2025 at the European Heart House 🇫🇷! Connect, learn & lead in cardiovascular care 💙 🗓️ Late fee registration closes 12 May! 🔗 Register now: escardio.org/Congresses-Eve… #CardioNursing #AlliedProfessionals European Society of Cardiology

#ACNAP2025 June 12-14 2025?☀️☀️

Watch the recording of our webinar on Health Inequalities with a focus on CVRM. youtu.be/NOSDX88IQo8?fe…

fozia ahmed delivers an excellent talk on “IV iron therapy in the context of 4 pillars” #HeartFailure2025

♻️ 💔Recovered EF ≠ recovered risk Finerenone delivers—LVEF history doesn’t change that 🔹 HFimpEF = 5% of trial pop, median EF rise: +12% 🔸 CV event rates still high (21.4 vs 16.0 per 100 pt-yrs) 🔹 Finerenone benefit consistent: RR 0.72 in HFimpEF 🔸 Greater absolute risk

Lp(a)-associated CAD risk seems to particularly affect those having levels of Total-C, LDL-C and TG above the thresholds from clinical guidelines

Beta-blocker interruption effects on blood pressure and heart rate after myocardial infarction AβYSS Trial (n=3698, 3.0 yrs FU): 📍β-blocker interruption led to ↑ SBP (+3.7), DBP (+3.3), HR (+10 bpm); all P < .001. 📍Effect seen in both HTN & non-HTN pts. 📍HTN pts had ↑ risk

GLP-1 receptor agonists - promising treatments for neurodegenerative diseases. Incretins beyond glucose control. Alessandro Morandi Prash Vas Dr Rajay Narain sciencedirect.com/science/articl…

Last day of ESH Annual Meetings #ESH2025 with great attendance & 🔥#science presentations Honoured to co-Chair #Hypertension in #Women oral presentations More details to post once start journey (>24 hr) home begins🙏

Lipid management post ACS is a team effort! Honored to join Dr Rani Khatib FESC, Prof Lis Neubeck and Lisa Gritzmacher in the #ACNAP #ESCWebinar entitled Lipids and ACS; a multidisciplinary approach to better outcomes This Friday, May 30th, at 6pm CEST! esc365.escardio.org/event/1992

Join our European Society of Cardiology ACNAPPresident webinar Lipids and acute coronary syndrome; a multidisciplinary approach to better outcomes. Friday 30 May 2025 At 5pm UK time Details and Registeration 👇 esc365.escardio.org/event/1992 Prof Lis Neubeck Konstantin Krychtiuk

❤️ Statins outperform stent technology in preventing in-stent neoatherosclerosis 🔦 highlighting that pathophysiology > engineering. This editorial reminds us: durable ASCVD prevention starts with biology, not just devices. #MedEd #CardioTwitter #MedTwitter #FOAMed European Society of Cardiology

Finerenone Reduces New-Onset Atrial Fibrillation Across the Spectrum of Cardio-Kidney-Metabolic Syndrome: The FINE-HEART Pooled Analysis The nonsteroidal MRA finerenone reduced the risk of new-onset AF/AFL across the CKM spectrum jacc.org/doi/10.1016/j.…